CA64082X2032
© Newsfile
13.12.2025
NGEN
LISTED
TSX
NervGen Pharma Announces Proposed Amendment to Warrants
News Preview
Vancouver, British Columbia--(Newsfile Corp. - December 12, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other traumatic and neurologic disorders, today announced that the Compa...
Themefolio
Profiler
Peergroup
© Newsfile
24.11.2025
NGEN
LISTED
TSX
NervGen Pharma Reports Third Quarter Financial Results and Provides Business Updates
News Preview
Expanded CONNECT SCI Study data demonstrated unprecedented durable improvement in function, independence, and quality of life in individuals living with chronic spinal cord injuryCompleted a U.S. Food and Drug Administration (FDA) Type C meeting in September; FDA confirmed that multiple regulatory routes are available to support approval of NVG-291...
Themefolio
Profiler
Peergroup
© Newsfile
24.11.2025
NGEN
LISTED
TSX
NervGen Pharma Announces Expanded CONNECT SCI Study Data Demonstrating Unprecedented Durable Improvement in Function, Independence, and Quality of Life in Chronic Spinal Cord Injury
News Preview
Week 16 follow-up data, coupled with blinded exit interviews conducted up to 364 days after the study period, confirm durable and wide-ranging upper and lower-body improvements compared to placeboParticipant-reported outcomes highlight substantial improvements in bladder control and muscle spasticity compared to placeboStatistically significan...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Newsfile
19.11.2025
NGEN
LISTED
TSX
NervGen Pharma Announces Closing of US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development
News Preview
Vancouver, British Columbia--(Newsfile Corp. - November 19, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other traumatic and neurologic disorders, today announced that it has co...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Newsfile
18.11.2025
NGEN
LISTED
TSX
NervGen Pharma Announces US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development
News Preview
Vancouver, British Columbia--(Newsfile Corp. - November 18, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other traumatic and neurologic disorders, today announced that...
Themefolio
Profiler
Peergroup
© Newsfile
26.08.2025
NGEN
LISTED
TSX
NervGen Pharma Reports Second Quarter Financial Results and Provides Letter to Shareholders
News Preview
Announced unprecedented Phase 1b/2a topline results in chronic spinal cord injury NVG-291 is the first pharmacologic candidate to demonstrate statistically significant improvement in corticospinal connectivity with clinically meaningful functional gainsOngoing comprehensive analysis of NVG-291's efficacy profile will support upcoming regulatory dis...
Themefolio
Profiler
Peergroup
© Newsfile
21.08.2025
NGEN
LISTED
TSX
NervGen Pharma's NVG-291-R Demonstrates Significant Functional Recovery in Department of Defense-Sponsored Preclinical Models of Traumatic Hearing Loss and Peripheral Nerve Injury
News Preview
Demonstrated significant hearing restoration in blast-induced sensorineural hearing loss modelsPromoted significant functional recovery and axonal regeneration in peripheral nerve injury modelsReinforced NVG-291's broad therapeutic potential with new data across three distinct injury modelsVancouver, British Columbia--(Newsfile Corp. - August 21, 2...
Themefolio
Profiler
Peergroup
© Newsfile
17.07.2025
NGEN
LISTED
TSX
NervGen Announces Leadership Transition to Support Strategic Growth and Expansion
News Preview
Chairman Dr. Adam Rogers Appointed Interim CEO Following Landmark Positive Chronic Spinal Cord Injury Trial ResultsVancouver, British Columbia--(Newsfile Corp. - July 17, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) (the "Company"), a clinical-stage biotechnology company developing innovative therapies for spinal cord injury (...
Themefolio
Profiler
Peergroup
© Newsfile
07.07.2025
NGEN
LISTED
TSX
NervGen Provides Quarterly "At-The-Market" Equity Program and Grant of Options Update
News Preview
Vancouver, British Columbia--(Newsfile Corp. - July 7, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biotech company dedicated to developing innovative treatments for spinal cord injury (SCI) and other neurological conditions, today provided a quarterly update with respect to the C...
Themefolio
Profiler
Peergroup
© Newsfile
03.07.2025
NGEN
LISTED
TSX
NervGen Strengthens Board Leadership to Accelerate Clinical and Corporate Growth
News Preview
Dr. Adam Rogers appointed chair as company advances toward key milestones following positive topline chronic cohort results of Phase 1b/2a CONNECT SCI StudyVancouver, British Columbia--(Newsfile Corp. - July 3, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative treatments f...
Themefolio
Profiler
Peergroup
© Newsfile
01.07.2025
NGEN
LISTED
TSX
NervGen Announces Clinical Leadership Transition as NVG-291 Continues to Advance Toward Late-Stage Development and Regulatory Milestones
News Preview
Vancouver, British Columbia--(Newsfile Corp. - July 1, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neuroreparative therapeutics, today announced that Daniel Mikol, MD, Ph.D., has resigned from his position as Chief Medical Officer in order to pursue new opportunities. Randall Ka...
Themefolio
Profiler
Peergroup
© Newsfile
18.06.2025
NGEN
LISTED
TSX
NervGen Announces Appointment of Randall Kaye, MD to Chief Medical Advisor Role
News Preview
Vancouver, British Columbia--(Newsfile Corp. - June 18, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neuroreparative therapeutics, today announced the appointment of Randall Kaye, MD, to the role of Chief Medical Advisor. Dr. Kaye, a current member of NervGen's Board of Directors...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
02.06.2025
NGEN
LISTED
TSX
Canadian Investment Regulatory Organization Trade Resumption - NGEN
News Preview
VANCOUVER, BC, June 2, 2025 /CNW/ - Trading resumes in:
Company: NervGen Pharma Corp.
TSX-Venture Symbol: NGEN
All Issues: No
Resumption (ET): 10:24:39 AM
CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. CIRO...
Themefolio
Profiler
Peergroup
© PR Newswire
02.06.2025
NGEN
LISTED
TSX
Canadian Investment Regulatory Organization Trading Halt - NGEN
News Preview
VANCOUVER, BC, June 2, 2025 /CNW/ - The following issues have been halted by CIRO
Company: NervGen Pharma Corp.
TSX-Venture Symbol: NGEN
All Issues: No
Reason: Single Stock Circuit Breaker
Halt Time (ET): 10:19:39 AM
CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading ha...
Themefolio
Profiler
Peergroup
© PR Newswire
02.06.2025
NGEN
LISTED
TSX
Canadian Investment Regulatory Organization Trade Resumption - NGEN
News Preview
VANCOUVER, BC, June 2, 2025 /CNW/ - Trading resumes in:
Company: NervGen Pharma Corp.
TSX-Venture Symbol: NGEN
All Issues: No
Resumption (ET): 10:15:54 AM
CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. CIRO...
Themefolio
Profiler
Peergroup
© PR Newswire
02.06.2025
NGEN
LISTED
TSX
Canadian Investment Regulatory Organization Trading Halt - NGEN
News Preview
VANCOUVER, BC, June 2, 2025 /CNW/ - The following issues have been halted by CIRO
Company: NervGen Pharma Corp.
TSX-Venture Symbol: NGEN
All Issues: No
Reason: Single Stock Circuit Breaker
Halt Time (ET): 10:10:54 AM
CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading ha...
Themefolio
Profiler
Peergroup
© PR Newswire
02.06.2025
NGEN
LISTED
TSX
Canadian Investment Regulatory Organization Trade Resumption - NGEN
News Preview
VANCOUVER, BC, June 2, 2025 /CNW/ - Trading resumes in:
Company: NervGen Pharma Corp.
TSX-Venture Symbol: NGEN
All Issues: No
Resumption (ET): 9:43:17 AM
CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. CIRO i...
Themefolio
Profiler
Peergroup
© PR Newswire
02.06.2025
NGEN
LISTED
TSX
Canadian Investment Regulatory Organization Trading Halt - NGEN
News Preview
VANCOUVER, BC, June 2, 2025 /CNW/ - The following issues have been halted by CIRO
Company: NervGen Pharma Corp.
TSX-Venture Symbol: NGEN
All Issues: No
Reason: Single Stock Circuit Breaker
Halt Time (ET): 9:38:17 AM
CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading ha...
Themefolio
Profiler
Peergroup
© PR Newswire
23.05.2025
NGEN
LISTED
TSX
Canadian Investment Regulatory Organization Trade Resumption - NGEN
News Preview
VANCOUVER, BC, May 23, 2025 /CNW/ - Trading resumes in:
Company: NervGen Pharma Corp.
TSX-Venture Symbol: NGEN
All Issues: No
Resumption (ET): 10:18:14 AM
CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. CIRO...
Themefolio
Profiler
Peergroup
© PR Newswire
23.05.2025
NGEN
LISTED
TSX
Canadian Investment Regulatory Organization Trading Halt - NGEN
News Preview
VANCOUVER, BC, May 23, 2025 /CNW/ - The following issues have been halted by CIRO
Company: NervGen Pharma Corp.
TSX-Venture Symbol: NGEN
All Issues: No
Reason: Single Stock Circuit Breaker
Halt Time (ET): 10:13:14 AM
CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading ha...
Themefolio
Profiler
Peergroup
© Newsfile
21.05.2025
NGEN
LISTED
TSX
NervGen Pharma to Present Topline Data for NVG-291 Phase 1b/2a Chronic Cohort Study at the American Spinal Injury Association Annual Scientific Meeting
News Preview
Vancouver, British Columbia--(Newsfile Corp. - May 21, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotechnology company dedicated to developing neuroreparative therapeutics, today announced that topline results from the chronic cohort of the ongoing Phase 1b/2a study of NVG-291 will be presented as an oral presentati...
Themefolio
Profiler
Peergroup
© Newsfile
16.05.2025
NGEN
LISTED
TSX
NervGen Pharma Grants Stock Options
News Preview
Vancouver, British Columbia--(Newsfile Corp. - May 16, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotechnology company dedicated to developing neuroreparative therapeutics, today announced that it has granted 600,000 incentive stock options (the "Options") to directors and employees of the company. The Options are e...
Themefolio
Profiler
Peergroup
© Newsfile
15.05.2025
NGEN
LISTED
TSX
NervGen Pharma Reports Q1 2025 Financial Results and Provides Operational Updates
News Preview
Completed last subject, last visit in the chronic cohort, data readout targeted for early June 2025Vancouver, British Columbia--(Newsfile Corp. - May 15, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotechnology company dedicated to developing neuro-reparative therapeutics, today reported its financial and operational...
Themefolio
Profiler
Peergroup
© Newsfile
07.05.2025
NGEN
LISTED
TSX
NervGen Pharma Announces Results of Annual General Meeting of Shareholders
News Preview
All resolutions submitted for approval were passed by shareholdersVancouver, British Columbia--(Newsfile Corp. - May 7, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, announces the results of its Annual General Meeting of Shareholders ("AGM") held on...
Themefolio
Profiler
Peergroup
© Newsfile
21.04.2025
NGEN
LISTED
TSX
NervGen Pharma to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference
News Preview
Vancouver, British Columbia--(Newsfile Corp. - April 21, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced its participation in the 2025 Bloom Burton & Co. Healthcare Investor Conference in Toronto, ON. Mike Kelly, President & CEO...
Themefolio
Profiler
Peergroup
© Newsfile
09.04.2025
NGEN
LISTED
TSX
NervGen Provides Quarterly "At-The-Market" Equity Program Update
News Preview
Vancouver, British Columbia--(Newsfile Corp. - April 9, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today provided a quarterly update with respect to the Company's previously announced at-the-market equity program (the...
Themefolio
Profiler
Peergroup
© Newsfile
03.04.2025
NGEN
LISTED
TSX
NervGen Pharma Reports 2024 Year-End Financial Results and Provides Business Updates
News Preview
Completed enrollment in the chronic cohort and commenced enrollment in the subacute cohort of its Phase 1b/2a clinical trial for lead drug candidate, NVG-291, in spinal cord injury (SCI)Initiated an expanded access protocol for NVG-291 for individuals with SCI who have participated in a NervGen clinical trial and meet specific eligibility criteriaP...
Themefolio
Profiler
Peergroup
© Newsfile
31.03.2025
NGEN
LISTED
TSX
NervGen Initiates Expanded Access Policy
News Preview
The U.S. Food and Drug Administration (FDA) informed the company that an expanded access protocol for NVG-291 may proceedThis news release constitutes a "designated news release" for the purposes of NervGen's prospectus supplement dated December 19, 2024 to its short form base shelf prospectus dated November 25, 2024.Vancouver, British Columbia--(N...
Themefolio
Profiler
Peergroup
© Newsfile
15.03.2025
NGEN
LISTED
TSX
NervGen Pharma Grants Stock Options
News Preview
Vancouver, British Columbia--(Newsfile Corp. - March 14, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that it has granted 545,000 incentive stock options (the "Options") to employees and consultants of the company, including 100,000...
Themefolio
Profiler
Peergroup
© Newsfile
05.03.2025
NGEN
LISTED
TSX
NervGen Pharma to Present at the Virtual Life Science Investor Forum
News Preview
Vancouver, British Columbia--(Newsfile Corp. - March 5, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that Mr. Mike Kelly, President & CEO, will be presenting at the Virtual Life Sciences Investor Forum hosted by OTC Markets Group...
Themefolio
Profiler
Peergroup
© Newsfile
18.02.2025
NGEN
LISTED
TSX
NervGen Pharma Grants Stock Options
News Preview
Vancouver, British Columbia--(Newsfile Corp. - February 18, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that it has granted 627,200 incentive stock options to the company's employees, including 505,200 to the company's Officers, exe...
Themefolio
Profiler
Peergroup
© Newsfile
06.02.2025
NGEN
LISTED
TSX
NervGen Completes Dosing of First Subject in Subacute Cohort of its Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury
News Preview
Vancouver, British Columbia--(Newsfile Corp. - February 6, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that the first subject has been enrolled and dosed in the subacute cohort of its Phase 1b/2a proof-of-concept, double-blind, rand...
Themefolio
Profiler
Peergroup
© Newsfile
29.01.2025
NGEN
LISTED
TSX
NervGen Pharma to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
News Preview
Vancouver, Canada--(Newsfile Corp. - January 29, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that Mr. Mike Kelly, President & CEO, will be participating in a fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences...
Themefolio
Profiler
Peergroup
© Newsfile
02.01.2025
NGEN
LISTED
TSX
NervGen Completes Enrollment in Chronic Cohort of its Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury
News Preview
Topline data from the chronic cohort is expected in Q2 2025Institutional Review Board (IRB) protocol amendment changes approved, and screening has been initiated for subacute cohortThis news release constitutes a "designated news release" for the purposes of NervGen's prospectus supplement dated December 19, 2024 to its short form base shelf prospe...
Themefolio
Profiler
Peergroup
© Newsfile
20.12.2024
NGEN
LISTED
TSX
NervGen Announces "At-The-Market" Equity Program
News Preview
Vancouver, British Columbia--(Newsfile Corp. - December 20, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, is pleased to announce that it has established an at-the-market equity program (the "ATM Program") that allows...
Themefolio
Profiler
Peergroup
© Newsfile
14.11.2024
NGEN
LISTED
TSX
NervGen Pharma Reports Q3 2024 Financial Results and Operational Updates
News Preview
Target enrollment in the chronic cohort of our Phase 1b/2a clinical trial of NVG-291 in individuals with spinal cord injury (SCI) is approaching completionNVG-300 preclinical test-of-concept studies in ischemic stroke, amyotrophic lateral sclerosis (ALS) and SCI underwayVancouver, British Columbia--(Newsfile Corp. - November 14, 2024) - NervGen Pha...
Themefolio
Profiler
Peergroup
© Newsfile
07.11.2024
NGEN
LISTED
TSX
NervGen Pharma to Present at the Stifel 2024 Healthcare Conference
News Preview
Vancouver, British Columbia--(Newsfile Corp. - November 7, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, announced today that Mr. Mike Kelly, President & CEO, will be participating in a fireside chat at the Stifel 2024 Healthcare Conference on Mo...
Themefolio
Profiler
Peergroup
© Newsfile
30.09.2024
NGEN
LISTED
TSX
NervGen Pharma Provides Update on Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury
News Preview
Target enrollment in the chronic cohort close to completionVancouver, British Columbia--(Newsfile Corp. - September 30, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced that target enrollment of the chro...
Themefolio
Profiler
Peergroup
© Newsfile
20.09.2024
NGEN
LISTED
TSX
NervGen Pharma to Present at the Unite 2 Fight Paralysis 19th Annual Science & Advocacy Symposium Focused on Spinal Cord Injury
News Preview
Vancouver, British Columbia--(Newsfile Corp. - September 20, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Daniel Mikol, MD, Ph.D., NervGen's Chief Medical Officer, will give an oral presentation...
Themefolio
Profiler
Peergroup
© Newsfile
16.09.2024
NGEN
LISTED
TSX
NervGen Pharma to Present at the 63rd International Spinal Cord Society Annual Scientific Meeting
News Preview
Vancouver, British Columbia--(Newsfile Corp. - September 16, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Daniel Mikol, MD, Ph.D., NervGen's Chief Medical Officer, will present at the 63rd Inter...
Themefolio
Profiler
Peergroup
© Newsfile
27.08.2024
NGEN
LISTED
TSX
NervGen Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference
News Preview
Vancouver, British Columbia--(Newsfile Corp. - August 27, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Mr. Mike Kelly, President & CEO, will be presenting at the H.C. Wainwright 26th Annual...
Themefolio
Profiler
Peergroup
© Newsfile
22.08.2024
NGEN
LISTED
TSX
NervGen Pharma Reports Q2 2024 Financial Results and Operational Updates
News Preview
Targeting to complete enrollment in the Phase 1b/2a chronic cohort in Q3 2024Protocol being amended to enhance enrollment and lessen burden on participants in the subacute cohortNVG-300 advanced into preclinical proof-of-concept studies in ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI)Vancouver, British Columbia--...
Themefolio
Profiler
Peergroup
© Newsfile
06.08.2024
NGEN
LISTED
TSX
NervGen Pharma to Present at the Canaccord Genuity 44th Annual Growth Conference
News Preview
Vancouver, British Columbia--(Newsfile Corp. - August 6, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Mr. Mike Kelly, President & CEO, will be presenting at the Canaccord Genuity 44th Annual...
Themefolio
Profiler
Peergroup
© Newsfile
02.08.2024
NGEN
LISTED
TSX
NervGen Pharma Grants Stock Options
News Preview
Vancouver, British Columbia--(Newsfile Corp. - August 2, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that the company has granted 30,000 incentive stock options to employees of the company and 15,000 incen...
Themefolio
Profiler
Peergroup
© Newsfile
22.07.2024
NGEN
LISTED
TSX
NervGen Pharma Appoints Neil Klompas to Board of Directors
News Preview
Seasoned pharmaceutical executive with extensive experience in high-growth life sciences companies joins NervGenLeadership appointment supports the company's mission to advance NVG-291 after the completion of the ongoing Phase 1b/2a studyVancouver, British Columbia--(Newsfile Corp. - July 22, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF)...
Themefolio
Profiler
Peergroup
© Newsfile
25.06.2024
NGEN
LISTED
TSX
NervGen Pharma to Advance NVG-300 into Preclinical Proof-of-Concept Stage
News Preview
New molecule demonstrates efficacy in a challenging SCI modelExpanding pipeline into new indications of ischemic stroke and ALSVancouver, British Columbia--(Newsfile Corp. - June 25, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous sy...
Themefolio
Profiler
Peergroup
© Newsfile
20.06.2024
NGEN
LISTED
TSX
NervGen Pharma to Present at the 2nd Annual Spinal Cord Injury Investor Symposium
News Preview
Vancouver, British Columbia--(Newsfile Corp. - June 20, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Mr. Mike Kelly, President & CEO, will be presenting a corporate update at the 2nd Annual...
Themefolio
Profiler
Peergroup
© Newsfile
07.06.2024
NGEN
LISTED
TSX
NervGen Pharma Grants Stock Options
News Preview
Vancouver, British Columbia--(Newsfile Corp. - June 6, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that the company has granted 950,000 incentive stock options to directors and consultants of the company e...
Themefolio
Profiler
Peergroup
© Newsfile
05.06.2024
NGEN
LISTED
TSX
NervGen Pharma Announces Results of Annual General Meeting of Shareholders
News Preview
All resolutions submitted for approval were passed by shareholdersGlenn Ives appointed as Chair of the BoardJohn Ruffolo appointed as Chair of the Audit CommitteeVancouver, British Columbia--(Newsfile Corp. - June 5, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutio...
Themefolio
Profiler
Peergroup
© Newsfile
17.05.2024
NGEN
LISTED
TSX
NervGen Pharma to Present Two Posters at the American Spinal Injury Association 51st Annual Scientific Meeting
News Preview
Vancouver, British Columbia--(Newsfile Corp. - May 17, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Daniel Mikol, MD, Ph.D., Chief Medical Officer, will be presenting two posters at the upcoming...
Themefolio
Profiler
Peergroup
© Newsfile
16.05.2024
NGEN
LISTED
TSX
NervGen Pharma Reports Q1 2024 Financial Results and Operational Updates
News Preview
Target for completing enrollment of the chronic cohort in the Phase 1b/2a clinical trial moved to Q3 2024Subacute cohort protocol being amended to enhance feasibility and lessen burden on participantsCA$23 million bought deal financing completed in March 2024 provides expected cash runway through Q3 2025 Vancouver, British Columbia--(Newsfile Corp....
Themefolio
Profiler
Peergroup
© Newsfile
07.05.2024
NGEN
LISTED
TSX
NervGen Files Management Information Circular and Announces Board of Directors Transition
News Preview
Bill Radvak to transition to Board Advisor following decision to not stand for re-election to NervGen's Board of DirectorsAnnual General Meeting of Shareholders to be held on June 4, 2024Vancouver, British Columbia--(Newsfile Corp. - May 7, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical-stage biote...
Themefolio
Profiler
Peergroup
© Newsfile
25.04.2024
NGEN
LISTED
TSX
NervGen Engages Russo Partners LLC to Provide Public Relations Services
News Preview
Vancouver, British Columbia--(Newsfile Corp. - April 25, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that it has engaged Russo Partners LLC ("Russo Partners"), a New York base...
Themefolio
Profiler
Peergroup
© Newsfile
17.04.2024
NGEN
LISTED
TSX
NervGen Pharma Reports 2023 Year-End Financial Results and Operational Updates
News Preview
Anticipated completion of enrollment of the chronic cohort in the Phase 1b/2a clinical trial in Q2 2024CA$23 million bought deal financing completed in March 2024 provides expected cash runway through Q3 2025 Fast Track designation granted by U.S. Food and Drug Administration (FDA) for NVG-291 in spinal cord injuryVancouver, British Columbia--(News...
Themefolio
Profiler
Peergroup
© Newsfile
28.03.2024
NGEN
LISTED
TSX
NervGen Completes $23 Million Bought Deal Financing
News Preview
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.Vancouver, British Columbia--(Newsfile Corp. - March 28, 2024) - NervGen Pharma Corp. (TSXV: NGEN) ("NervGen" or the "Company") is pleased to announce the closing of its previously announced public offering (the "Offering") including the full exe...
Themefolio
Profiler
Peergroup
© Newsfile
21.02.2024
NGEN
LISTED
TSX
NervGen Pharma Recognized as a Top 50 TSX Venture Exchange Company
News Preview
Vancouver, British Columbia--(Newsfile Corp. - February 21, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, has been recognized by the TSX Venture Exchange as a 2023 Top 50 Company. The 2024 TSX Venture 50™ showc...
Themefolio
Profiler
Peergroup
© Newsfile
20.02.2024
NGEN
LISTED
TSX
NervGen Pharma Grants Stock Options
News Preview
Vancouver, British Columbia--(Newsfile Corp. - February 20, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced that it has granted incentive stock options to the Company's employees, including 505,200 to t...
Themefolio
Profiler
Peergroup
© Newsfile
15.02.2024
NGEN
LISTED
TSX
NervGen Pharma on Track to Complete Enrollment, Deliver Data Readout in Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury
News Preview
On track to complete enrollment of the chronic cohort in Q2 2024Data readout from chronic cohort expected in Q3 2024Planning underway to make NVG-291 available to placebo-treated subjects following cohort completion Vancouver, British Columbia--(Newsfile Corp. - February 15, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stag...
Themefolio
Profiler
Peergroup
© Newsfile
09.11.2023
NGEN
LISTED
TSX
NervGen Pharma Reports Q3 2023 Financial Results and Operational Updates
News Preview
Phase 1a/2b clinical trial of NVG-291 underway with dosing of individuals with spinal cord injury; results from chronic cohort expected in mid-2024 Fast Track designation granted by U.S. Food and Drug Administration (FDA) for NVG-291 in spinal cord injurySeasoned financial industry executive, John Ruffolo, appointed to BoardVancouver, British Colum...
Themefolio
Profiler
Peergroup
© Newsfile
08.11.2023
NGEN
LISTED
TSX
Neuroscientist and NervGen Pharma Scientific Founder, Dr. Jerry Silver, Interviewed on 'Remarkable People' Podcast Hosted by Tech Luminary Guy Kawasaki
News Preview
Dr. Silver's life work, culminating in NervGen's NVG-291, is currently in a Phase 1b/2a clinical trial for individuals with spinal cord injury.Vancouver, British Columbia--(Newsfile Corp. - November 8, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the trea...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
